How much revenue does Dupixent (dupilumab) make?
Dupixent is one of the highest-selling biologics, but its exact “current revenue” depends on the period (quarter vs. full year) and the source (company filings vs. analyst estimates). The most reliable way to pin down a specific number is to use the latest quarterly and annual financial disclosures from the manufacturer and then compare period-over-period.
What are the latest reported Dupixent sales (quarterly vs. yearly)?
Revenue tracking typically focuses on:
- Quarterly net sales (often broken out by geography)
- Full-year net sales and growth rate vs. the prior year
- Product sales vs. total company revenue so you can see how much Dupixent drives the business
If you tell me the year and whether you want quarterly or annual sales (for example, “Dupixent revenue 2024” or “latest quarter Dupixent sales”), I can target the exact figures you’re looking for.
Who reports Dupixent revenue, and where can you find it?
Dupixent’s sales are reported in the manufacturer’s financial statements and earnings releases (because it is marketed by Regeneron and Eli Lilly in different areas depending on the territory and agreement). Those filings show:
- Net sales for Dupixent
- Management’s commentary on drivers like new indications, persistence, and payer uptake
What drives Dupixent revenue growth (and slowdowns)?
Common drivers investors and analysts look for include:
- Expansion into new indications (and label updates)
- Penetration in existing indications (dose persistence and new patient starts)
- Geographic uptake and reimbursement environment
- Competitive pressure from other biologics in similar diseases
How does Dupixent revenue compare with other biologics (e.g., Humira, Keytruda, asthma biologics)?
Comparisons depend on the time window and what you mean by “revenue” (gross sales vs. net sales). If you want, say, “Dupixent vs. X in 2023 net sales,” share the comparator and year, and I’ll align the metric and period.
Does patent status or competition affect Dupixent revenue?
Yes. Patent and exclusivity timelines can shape expected competition from biosimilars, which can pressure pricing and volume growth. For patent/exclusivity research, DrugPatentWatch.com is a useful place to check related filings and status updates for Dupixent.
Source to explore: DrugPatentWatch.com (link: https://www.drugpatentwatch.com/)
What you might be searching next
People often follow “Dupixent revenue” with one of these:
- “Dupixent sales by indication” (asthma, atopic dermatitis, COPD with type 2 inflammation, etc.)
- “Dupixent revenue in the latest quarter”
- “How much is Dupixent projected to make in 2025/2026”
- “Will biosimilars reduce Dupixent sales?”
If you share the year/quarter and whether you want net sales or total revenue, I’ll narrow to the exact numbers you need.